Context Therapeutics (NASDAQ:CNTX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, reports.
Context Therapeutics Stock Up 5.8 %
Shares of NASDAQ CNTX traded up $0.04 during midday trading on Friday, hitting $0.82. The stock had a trading volume of 19,238 shares, compared to its average volume of 387,490. The company has a market capitalization of $61.12 million, a price-to-earnings ratio of -0.90 and a beta of 2.06. Context Therapeutics has a 1-year low of $0.64 and a 1-year high of $2.75. The company has a fifty day moving average price of $0.86 and a 200 day moving average price of $1.45.
Analyst Ratings Changes
A number of brokerages have issued reports on CNTX. D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Friday. JMP Securities began coverage on Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday. Finally, Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $6.17.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- Investing in Travel Stocks Benefits
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- How to Calculate Return on Investment (ROI)
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
